Company news

CNS Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CNS Provides Update on Development Agreement for WP1122

May 26, 2020

CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

May 26, 2020

CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information

May 17, 2020

CNS Pharmaceuticals Announces Trading Halt

May 3, 2020

CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin

April 22, 2020

CNS Pharmaceuticals Announces Shareholder Webinar to Discuss Collaboration with WPD Pharmaceuticals for Developing Coronavirus Drug Candidates, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

April 14, 2020

CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals

April 12, 2020

CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets

March 22, 2020

CNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results

March 11, 2020

CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020

March 4, 2020

CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free

March 2, 2020

CNS Pharmaceuticals to Ring Nasdaq Stock Market Opening Bell on March 3

February 26, 2020

CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors

February 10, 2020

CNS Pharmaceuticals Announces Completion of GMP Manufacturing

February 3, 2020

CNS Pharmaceuticals Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance

January 27, 2020

CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin

January 13, 2020

CNS Pharmaceuticals Licenses Breakthrough Technology from MD Anderson, Doubling its Drug Pipeline

January 12, 2020

CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals

November 25, 2019

CNS Pharmaceuticals Announces Full Exercise of Over-Allotment Option

November 20, 2019

CNS Pharmaceuticals Announces Attendance at the 24th Annual Meeting of the Society of Neuro-Oncology

November 19, 2019

CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock

November 12, 2019

← Newer news releases

Decks

The 5 newest of 24 decks. Every deck is listed under its year.